Our study investigated for the first time the serum levels of TGF β1 in patients with and without bone metastasis and identified that both breast cancer patients with and without bone metastases had significantly lower levels compared to healthy age-matched controls.
In our study, breast cancer patients with or without bone metastases had increased OPG levels compared to healthy controls, contrasting with the absence of elevation found by Lipton et al (2002).
OVX rats also showed a significant increase in plasma NTx levels compared to Sham rats indicating increased bone resorption.
Scaffolds alone did not induce comparable levels of bone formation compared to the autograft and rhBMP-7 groups.
Serum TRACP5b levels were on average 95% higher in patients who will develop bone metastases compared to levels in patients who did not develop bone metastases although the difference did not reach statistical significance (P=0.08).
However, all of these genes, except C/EBPβ, were expressed at relatively lower levels in bone marrow compared to epididymal adipocytes.
The patients with dental amalgam fillings (DA) who had been exposed mainly to THg, Cd, and Zn contained in amalgams showed no statistically significant differences in element levels in bone tissue compared to the patients without amalgam fillings (NDA), despite higher THg concentrations in the patients with DA (over 1.5 times higher) than the NDA patients (0.0061 versus 0.0039 mg/kg dm).
The high cholesterol level in PCa bone metastases as compared to normal bone (P = 3.12E-5, Figure 3a) was clearly verified in the test set data (P = 0.001, Figure 3b).
Cross-sectional studies of ART-naive HIV-infected patients found altered levels of bone turnover markers, in accordance with a reduced level of bone formation when compared to HIV-uninfected controls (Haskelberg et al., 2011).
The results in Figure 3C indicate the one-step method of isolating RNA from bone yields significantly higher levels of PPARγ in bone when compared to the currently used approach.
